On February 5, 2021 Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, reported the pricing of its initial public offering of 9,828,017 shares of its common stock at a price to the public of $18.00 per share (Press release, Vor BioPharma, FEB 5, 2021, View Source [SID1234574708]). The gross proceeds to Vor from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Vor, are expected to be approximately $176.9 million. In addition, Vor has granted the underwriters a 30-day option to purchase up to an additional 1,474,202 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions. All of the shares of common stock are being offered by Vor.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The shares are expected to begin trading on the Nasdaq Global Market on Friday, February 5, 2021, under the ticker symbol "VOR". The offering is expected to close on Tuesday, February 9, 2021, subject to customary closing conditions.

Goldman Sachs and Co. LLC, Evercore ISI, Barclays and Stifel are acting as joint book-running managers for the offering.

Registration statements relating to the securities being sold in this offering have been filed with the Securities and Exchange Commission (SEC) and have become effective. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. This offering is being made only by means of a prospectus forming part of the effective registration statements relating to these shares. Copies of the final prospectus may be obtained, when available, from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone at 1-866-471-2526, or via email at [email protected]; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, via telephone at 1-888-474-0200, or via email at [email protected]; Barclays Capital Inc., Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, via telephone at 1-888-603-5847, or via email at [email protected]; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, via telephone at 1-415-364-2720, or via email at [email protected].

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

On February 5, 2021 TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, reported financial results for the fiscal year ended December 31, 2020 and provided a business update (Press release, Taiwan Liposome Company, FEB 5, 2021, View Source [SID1234574690]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"In the tumultuous year that was 2020, we were fortunate enough to have achieved early patient enrollment in the Phase II clinical trial of our postsurgical pain program before COVID-19 began its spread to the United States," commented George Yeh, President of TLC. "And in the midst of the pandemic, we managed to complete full patient enrollment in the pivotal trial of our osteoarthritis pain program and continue the global expansion of Ampholipad, all while initiating a clinical trial for inhalable liposomal hydroxychloroquine as a potential treatment for severe lung diseases such as COVID-19. We hope the application of our proprietary technologies can help to put an end to the pandemic. To resonate with the name of our pivotal trial for our osteoarthritis pain program, EXCELLENCE, we will continue to strive for excellence in this very important year to provide the most benefits for patients, physicians and stakeholders alike."

Clinical Pipeline Update and Upcoming Milestones

Following the completion of patient enrollment, 500 patients have received their first injection of TLC599, dexamethasone sodium phosphate or normal saline in EXCELLENCE, the Phase III pivotal clinical trial of TLC599 for symptomatic knee osteoarthritis. Majority of the patients who are due for Week 24 have received a second injection of either TLC599 or placebo. The multi-center, randomized, double-blind, active comparator- and placebo-controlled pivotal study is evaluating the efficacy and safety of a single, as well as a repeat, dose of TLC599 in patients with knee OA across 41 sites in the United States and five sites in Australia.
Preparations for pivotal studies of TLC590 for postsurgical pain management are underway, with planned End-of-Phase-2 meetings to occur in 2021 with the United States Food and Drug Administration (FDA) on the design of the clinical trials and production preparations.
Published peer-reviewed manuscript in Clinical and Translational Science Journal, presenting the feasibility of applying TLC’s inhalable liposome technology to drugs for direct delivery to – and extended release in – the lungs, as endorsed by key opinion leaders in respiratory therapies. A Phase I randomized, vehicle-controlled, blinded study evaluating the safety, tolerability, and pharmacokinetics of TLC19 (inhalable liposomal hydroxychloroquine) in healthy volunteers is ongoing.
Corporate Highlights

Completed US$15 million financing for InspirMed Inc., a newly established subsidiary that specializes in the development of inhalable liposome formulation programs, such as TLC19, for severe acute and chronic pulmonary diseases. The strategic move to partition lung disease programs from TLC will allow TLC to maintain focus on its current pipeline of liposomal injectable formulation programs, including TLC599 and TLC590.
Commercialization of Ampholipad advancing smoothly, with a non-binding term sheet for commercialization in a specified territory in Latin America recently signed and review of the formal agreement underway. In Asia, China’s National Medical Products Administration is reviewing the Marketing Authorization Application of the generic liposomal amphotericin B drug. Worldwide discussions for partnership opportunities are ongoing.
Held investor conference and attended JP Morgan Healthcare Conference. The management team of TLC presented the latest company updates during the virtual investor conference hosted by KGI Securities, as well as at JP Morgan Healthcare Conference, the largest annual biotech event in the world, which was also conducted virtually due to the COVID-19 pandemic.
Expanded global intellectual property protection to 257 patents, with 160 patents granted and 97 applications worldwide as of December 31, 2020.
Fiscal Year End 2020 Financial Results

Operating revenue for the fiscal year 2020 was NT$101.9 million (US$3.6 million), a 51.3% decrease compared to NT$209.1 million (US$7.0 million) in the fiscal year 2019. Operating expenses for the fiscal year 2020 was NT$1,113.3 million (US$39.6 million), an 8.4% increase compared to NT$1,026.8 million (US$34.3 million) in the fiscal year 2019. Net loss for the fiscal year 2020 was NT$983.3 million (US$35.0 million), compared to a loss of NT$807.5 million (US$27.0 million) in the fiscal year 2019, or a net loss of NT$12.42 (US$0.44) per share for the fiscal year 2020, compared to a net loss of NT$12.32 (US$0.41) per share for the fiscal year 2019.

The Company’s cash and cash equivalents were NT$1,342.7 million (US$47.8 million) as of December 31, 2020, compared to NT$1,023.9 million (US$34.2 million) as of December 31, 2019.

On February 5, 2021 argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, reported the closing of its previously announced global offering of an aggregate of 3,593,750 ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)), which includes the full exercise of the underwriters’ option to purchase 468,750 ordinary shares in the form of ADSs (Press release, argenx, FEB 5, 2021, View Source,aggregate%20of%203%2C593%2C750%20ordinary%20shares [SID1234574709]). The gross proceeds from the global offering were approximately $1.15 billion (approximately €954.8 million).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

J.P. Morgan, Morgan Stanley, BofA Securities and Cowen acted as joint bookrunning managers for the offering.

The securities were offered in the United States pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission (SEC). A preliminary prospectus supplement relating to the securities was filed with the SEC on February 1, 2021 and a final prospectus supplement relating to the securities was filed with the SEC on February 4, 2021 and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the U.S. offering may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at [email protected]; from Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attn: Prospectus Department, by email at [email protected], or by telephone at (866) 718-1649; from BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, North Carolina 28255-0001, Attn: Prospectus Department, or by email at [email protected]; or from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by email at [email protected], or by telephone at (833) 297-2926.

In addition, argenx announces the listing of and the commencement of dealings in its 3,593,750 new ordinary shares on the regulated market of Euronext Brussels.

This press release is for information purposes only and does not constitute, and should not be construed as, an offer to sell or the solicitation of an offer to buy or subscribe to any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale is not permitted or to any person or entity to whom it is unlawful to make such offer, solicitation or sale. Reference is also made to the restrictions set out in "Important information" below. This press release is not for publication or distribution, directly or indirectly, in or into any state or jurisdiction into which doing so would be unlawful or where a prior registration or approval is required for such purpose.

On February 5, 2021 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported that members of its senior management team are scheduled to participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021, at 3:30 p.m. ET (Press release, CRISPR Therapeutics, FEB 5, 2021, View Source [SID1234574675]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be available on the "Events & Presentations" page in the Investors section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 14 days following the presentation.

On February 5, 2021 Kureha Corporation reported that FY2020 3Q Results (Press release, Kureha Corporation, FEB 5, 2021, View Source [SID1234574710])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

I. Highlights
FY2020 3Q results (year-on-year analysis)
• Delivered core operating profit of ¥14.6bn (+12.1%, ¥1.6bn) driven by PVDF (LiB binder applications), agrochemicals, home products, fishing lines and environmental businesses; lower fuel and raw materials cost; and fewer SG&A expenses • Operating profit decreased to ¥14.6bn (-43.5%, ¥11.2bn) for the absence of other income such as a gain from land sales

✓ Limited impact of the coronavirus pandemic on sales and production operations
✓ Advanced Materials: continued demand for PVDF in automotive LiB binder applications in EU and China; PGA frac plug volumes improved with new flexible prices while shale fracking activities gradually returned with crude oil prices going over $50/bbl
✓ Specialty Plastics: continued robust sales of home products and fishing lines; slower demand for multilayer shrink film in EU; negative effects of business divestment related to blow bottles
FY2020 full-year outlook

• Upgraded FY2020 guidance based on higher sales volumes expected in Advanced Materials and environmental businesses and less-than-expected SG&A expenses Current guidance Previous guidance ChII. FY2020 3Q Results (Period April 1, 2020 – December 31, 2020) Revenue improved primarily due to higher sales volumes in Other Operations, partially offset by Specialty Plastics

• Core operating profit grew in all segments except Advanced Materials
• Operating profit decreased due largely to fewer non-operating income such as a gain from land sales
• Profit attributable to the Company decreased as a result of lower operating profit and lower profit before taxesAM: Lower profit led by PPS, PGA and carbon products, partially offset by improved PVDF performance SC: Higher profit driven by agrochemicals and pharmaceuticals despite a decline in industrial chemicals SP: Higher profit driven by home products and fishing lines despite a decline in packaging materials CO: Profit even with prior year due to project cancellations/postponements in private sector offsetting higher civil engineering volumes OO: Higher profit driven by volume growth related to low-level PCB waste treatment and 2019 typhoon disaster wastes in Fukushima in the environmental engineering business Revenue Operating profit Segment results FAdvanced plastics PPS: Profit declined on lower sales volumes for automobile applications and lower equity income in affiliates PVDF: Higher profit driven by volume growth for LiB binder applications, partially offset by declines in other applications PGA: Profit down due to declined sales of frac plugs and stock shapes, although shale drilling activities gradually returned in 3Q Carbon products Lower profit led by slower carbon fiber sales for automobile and furnace insulation applications Other Profit improved on higher adhesive volumesVs.

FY2019 3Q Revenue Operating Profit 9 Agrochemicals Higher profit driven by fungicides volume growth Pharmaceuticals Profit improved on lower expenses, despite sales negatively affected by mandatory drug price revisions Industrial chemicals Profit down due to slower demand for organic and inorganic chemicals amid COVID-related slumpVs.

FY2019 3Q Revenue Operating Profit 10 Home products / Fiber products Profit growth driven by higher home products and ‘Seaguar’ fishing lines volumes Packaging materials Sales and profit declined due to slower demand for heat-shrink multilayer film for meat packaging in EU under the pandemic, coupled with negative effects of the blowbottle business divested in prior yearConstruction Revenue declined and profit remained on par with prior year as higher civil engineering sales volumes offset the cancellation and postponement of privatesector construction Environmental engineering Profit increased on higher volumes of lowlevel PCB wastes and 2019 typhoonrelated disaster wastes in Fukushima Logistics Revenue and profit remained at prior year’s levels Hospital operations Revenue and profit decreasedIII.

FY2020 Full-Year Outlook (Period April 1, 2020 – March 31, 2021)Revenue expected to decrease due to:-Slower demand for PGA in the shale market-Effects of the bottle business divestment-Slower demand for industrial chemicals partly offset by-Higher PVDF volume for LiB binder applications-Sales expansion in the environmental business

• Core operating profit to increase on volume growth of value-added products such as PVDF and environmental services, partially offset by declines in PGA, packaging materials and industrial chemicals
• Operating profit to decline primarily due to the absence of other income such as a gain from land sales
• Profit before taxes to decrease on lower operating profit
• Profit attributable to the Company to decrease on lower profit before taxesFactors attributing to operating profit (vs. FY2019) Advanced Materials Specialty Chemicals Specialty Plastics Construction Other Operations Advanced Materials Specialty Chemicals Specialty Plastics Construction Other Operations (in billions of yen) AM: Operating loss for PGA, partially offset by higher PVDF volume SC: Improved demand for agrochemicals after prior year’s inventory adjustments SP: Higher fishing line sales volume offset by volume declines in packaging materials CO: Fewer high-margin projects, intensified market competition OO: Higher treatment volumes related to low-level PCB wastes and Fukushima’s typhoon disaster wastesFactors attributing to operating profit (vs. previous guidance) Advanced Materials Specialty Chemicals Specialty Plastics Construction Other Operations Advanced Materials Specialty Chemicals Specialty Plastics Construction Other Operations (in billions of yen) AM: Higher PVDF volumes for automotive LiB binder applications; no change for PGA SC: (No change) SP: Improved product mix for home products and lower expenses CO: (No change) OO: Higher treatment volumes of low-level PCB wastes and Fukushima typhoon disaster wastesIV. SupplementaryShale oil and gas production decreased sharply during 2020, but drilling and fracking operations are gradually returning in key markets

• Kureha’s sales expansion strategy:-Increase sales volumes of PGA frac plugs by offering flexible prices in mid-and hightemperature well areas-Introduce and expand sales of non-PGA dissolvable frac plugs in extremely low temperature areas (currently under field trials)
• Kureha maintains a roughly 40% share in the automotive LiB cathode binder market; supplies to major South Korean and Chinese lithium-ion battery (LiB) makers
• After COVID-related disruption for LiB production in early 2020, the market is rapidly recovering on the back of tighter environmental regulations and economic stimulus policies
• Kureha’s China plant started production and shipment of specialty binder grade of PVDF in May 2020
• Studies for a new PVDF plant under review (delayed due to the pandemic):-To be located in China-Outlines of the new plant to be announced by Spring 2021-Will start commercial production in FY2024These materials are supplied to provide a deeper understanding of our company, and are not intended to as a solicitation for investment or other actions.
• These materials have been prepared by our company based on the information available at this point in time. However, actual performance may produce results that differ from the plan due to unforeseeable events and factors.
• Please utilize these materials using you own judgment and responsibility.